Clopidogrel in Critically Ill Patients.

about

Reduction of Premature Aging Markers After Gastric Bypass Surgery in Morbidly Obese Patients.

P2860

Q52716853-B6B85BD0-A6DF-4615-9311-D248EBEAF521

P2860

Clopidogrel in Critically Ill Patients.

Item

http://www.wikidata.org/entity/Q47980408

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Clopidogrel in Critically Ill Patients.

@en

Clopidogrel in Critically Ill Patients.

@nl

type

Item

label

Clopidogrel in Critically Ill Patients.

@en

Clopidogrel in Critically Ill Patients.

@nl

prefLabel

Clopidogrel in Critically Ill Patients.

@en

Clopidogrel in Critically Ill Patients.

@nl

P1476

Clopidogrel in Critically Ill Patients.

@en

P2093

Bernd Jilma

http://www.w3.org/2001/XMLSchema#string

Eva-Luise Hobl

http://www.w3.org/2001/XMLSchema#string

Gottfried Heinz

http://www.w3.org/2001/XMLSchema#string

Matthias Hackl

http://www.w3.org/2001/XMLSchema#string

Monika Schmid

http://www.w3.org/2001/XMLSchema#string

Peter Schellongowski

http://www.w3.org/2001/XMLSchema#string

Raute Sunder-Plaßmann

http://www.w3.org/2001/XMLSchema#string

Thomas Stimpfl

http://www.w3.org/2001/XMLSchema#string

Walter S Speidl

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el

P2Y12-ADP receptor antagonists: Days of future and past

Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications

Response variability to P2Y12 receptor inhibitors: expectations and reality

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.

Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial.

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers

Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system.

P304

217-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.878

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Jolanta M Siller-Matula

Christian Schoergenhofer

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28913918

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

P932

5813104

http://www.w3.org/2001/XMLSchema#string

Clopidogrel in Critically Ill Patients.

about

P2860

P2860

Clopidogrel in Critically Ill Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932